Clinical trial · Interventional
Study of Coronary Calcium Score as a Marker of Post-radiation Vascular Dysplasia in Adults Treated During Childhood for Cancer With Mediastinal Irradiation
NCT03604627CI-TRIAL-00077547COROCANrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To measure coronary calcium score in adults treated during childhood or adolescence for irradiation cancer in the heart and / or anthracycline area and compare them to determine whether irradiation of the heart area is associated with increased calcium score after adjustment for other cardiovascular risk factors (age, sex, smoking, dyslipidemia, obesity, diabetes, high blood pressure and renal failure).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coronal calcium score measurement | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients treated for cancer during childhood or adolescence
- description
- Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg/m\^²)
- interventionNames
- Other: Coronal calcium score measurement
Primary outcomes (1)
- measure
- Incidence of a calcium score
- timeFrame
- Up to 24 months
- description
- Incidence of a calcium score measured by the Agatston score\> 0 in the study population of adults treated during childhood or adolescence for cancer with irradiation of the heart area and / or treatment with anthracyclines
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients 18 years of age or older, 2. Treated for cancer during childhood, adolescence or young adulthood (≤25 years), 3. Treated with irradiation of the heart area (≥20% of ≥5Gy heart rate) and / or anthracycline (cumulative dose of doxorubicin equivalent ≥300mg/m\^²), 4. In complete remission of their pediatric cancer for at least 10 years, 5. Patient affiliated to a social security scheme or beneficiary of such a scheme, 6. Patient Information and Signed Informed Consent. Exclusion Criteria: 1. Perspective less than 10 years, 2. Persons deprived of liberty or guardianship (including trusteeship), 3. Impossibility of submitting to the medical follow-up of the test for geographical, social or psychological reasons, 4. Pregnant women. Inclusion criteria for extension cohort: 1. Patients 30 years of age or older, 2. Treated for cancer during childhood, adolescence or young adulthood (≤25 years), 3. Treated with irradiation of the heart area (≥20% of ≥5Gy heart rate), 4. In complete remission of their pediatric cancer for at least 10 years, 5. Patient affiliated to a social security scheme or beneficiary of such a scheme, 6. Patient Information and Signed Informed Consent. Exclusion criteria for extension cohort: 1. Persons deprived of liberty or guardianship (including trusteeship), 2. Impossibility of submitting to the medical follow-up of the test for geographical, social or psychological reasons, 3. Pregnant women.
References
Publications (0)
Data not yet available
No reference posted for this study.